Partnership Potential Position Scancell as a strategic collaboration target for oncology players by licensing or co-developing its off-the-shelf vaccines and tumor-targeting antibodies. Leverage Phase 2 efficacy signals in metastatic melanoma and other solid tumors to accelerate late-stage development and bring solutions to market faster.

Pipeline Licensing Monetize SCOPE and ModiFY programs across solid tumors through regional or global licensing deals, enabling scalable deployment of immunotherapy platforms to a broader patient base.

Funding Leverage With both early revenue and additional funding, there is room for partnerships that provide milestone-based financing to accelerate trials and manufacturing scale, reducing risk for a partner while expanding Scancell's clinical footprint.

Regional Access The Oxford, UK base offers proximity to European clinical networks and manufacturing ecosystems, presenting opportunities for regional manufacturing agreements and joint trials that streamline regulatory pathways.

Market Differentiation The off-the-shelf vaccine platform combined with immune cell redirection strategies offers a competitive edge in immuno-oncology by enabling faster production, easier logistics, and broader patient access compared to bespoke therapies.